Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may be safe, tolerable and/or effective in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Cedars-Sinai Medical Center — Los Angeles, California
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard — Fort Wayne, Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview — Fort Wayne, Indiana
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
- National Cancer Institute — Rockville, Maryland
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Charlestown, Massachusetts
- Newton-Wellesley Hospital — Newton, Massachusetts
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Fallopian Tube Carcinoma
Explore by condition: All Fallopian Tube Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.